HOPES DIED WITH NEW STUDY
Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial
Cancer
- Arjun V. Balar,
- Andrea B. Apolo
-
- WAS A NEGATIVE STUDY THAT FAILED TO SHOW BENEFIT FOR THE ADDITION OF AVASTIN. WILL AN ONGOING PHASE III SAVE THE DAY, WE ARE WAITING!
-
-
- ===========================================================
- THIS ONE NEW COMPOUND IS ATTRACTING ATTENTION NOW
-
-
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and
Prostate Cancer
- Sören Lehmann⇓,
- Vladimir J.N. Bykov,
WE WILL HEAR MORE ABOUT THIS SINCE THE PRODUCT SEEMS TO REACTIVATE A MUTATED P53. REACTIVATING A MUTATED P53 GENE, REALLY? THIS COMPOUND IS ACHIEVING A DREAM EFFECT. CAN YOU IMAGINE RESURRECTING A DEAD GENE, I WANT TO KNOW HOW IT WORKS!
No comments:
Post a Comment